Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Recommendation of “Buy” from Analysts

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) has earned an average rating of “Buy” from the eight ratings firms that are covering the company, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $12.6250.

Separately, Wedbush reissued an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, May 5th.

Institutional Trading of Perspective Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Taylor & Morgan Wealth Management LLC grew its stake in Perspective Therapeutics by 127.6% in the second quarter. Taylor & Morgan Wealth Management LLC now owns 66,000 shares of the company’s stock worth $225,000 after purchasing an additional 37,000 shares in the last quarter. Seven Fleet Capital Management LP purchased a new position in Perspective Therapeutics during the 1st quarter worth $1,581,000. Avidity Partners Management LP raised its position in Perspective Therapeutics by 88.4% during the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock valued at $25,228,000 after purchasing an additional 2,839,266 shares in the last quarter. Ally Bridge Group NY LLC bought a new stake in Perspective Therapeutics during the 1st quarter valued at $3,864,000. Finally, Yu Fan purchased a new stake in shares of Perspective Therapeutics in the 1st quarter worth $4,401,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Trading Down 0.7%

NYSEAMERICAN:CATX opened at $2.95 on Friday. Perspective Therapeutics has a twelve month low of $1.96 and a twelve month high of $6.16. The stock has a fifty day simple moving average of $3.33 and a 200-day simple moving average of $3.90.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. The firm had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.16 million. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 42.33%. Research analysts forecast that Perspective Therapeutics will post -1.1 earnings per share for the current fiscal year.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.